Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1 - Wikidata - awgldk - TriplyDB

Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1

Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1

http://www.wikidata.org/entity/Q35122067

about

A Blueprint for HIV Vaccine Discovery Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04 HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1 Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition.Rational antibody-based HIV-1 vaccine design: current approaches and future directions Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccination Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers.Increased functional stability and homogeneity of viral envelope spikes through directed evolution.Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected.Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides.Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies.Development of prophylactic vaccines against HIV-1.Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers.Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques.Native-like Env trimers as a platform for HIV-1 vaccine design.Trimeric gp120-specific bovine monoclonal antibodies require cysteine and aromatic residues in CDRH3 for high affinity binding to HIV Env.Role of adjuvants in modeling the immune response.HIV envelope: challenges and opportunities for development of entry inhibitors.HIV-1 vaccine immunogen design strategies.New approaches to HIV vaccine development.Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.

P2860

Q26829865-11E20808-3545-45F7-BF56-1214AEA47C57 Q27319450-7C1AE62F-D3BF-4012-93C6-C79BD1B2919D Q27675468-F9A8FBF1-E8FE-48E6-B236-C26D8AAAAC3E Q28647225-34EEF05C-625B-4203-B9E6-64297F1433D7 Q28743092-9543E416-FB9C-464B-B8CF-0AB18BADBAAD Q30353580-FA501AB9-5CBD-4FF4-8D77-A3367393E5A5 Q30490942-287A3A46-C841-4AA2-9369-3C82A24ECF33 Q33614461-507B1028-F61A-43D0-9C8F-29ED7E8E4760 Q33683203-B32ECEA4-F5FC-404E-BE2B-D2C2EF98A8B7 Q33719511-EE4EF530-3F91-49FA-98D9-0C41E0C5CE83 Q33725679-B74A9B9E-A2B4-4175-92B3-046AF4043DF7 Q33821896-83A1F8EE-226D-4E2E-9014-88C1AA4DE740 Q33937285-E3D0FBBB-4068-4C37-B6A1-18D72118D190 Q34074750-C635427E-DBE2-46E2-B610-E1209D09C446 Q34133551-3D83ABA1-15D5-4F9B-86AC-E8641B0BC5BE Q34204047-89B5CD56-A3B0-452E-8187-7028B852454F Q34285680-E427094C-CED8-4240-8DC3-A7ABE8616FB0 Q34611144-91439747-BFFC-45E7-9BF7-0A58E69FA348 Q34984724-BC231741-AE45-4EF0-A62A-66431683B8FE Q35076987-06F36E26-FE33-4E3A-871C-2FF05566F8DB Q35105223-CCF9E0DD-D26C-41B1-A147-7BA3B9271E3A Q35580892-74401B0F-A3FE-4668-9F5C-5BAF29FF5595 Q35689608-DC691DAD-5E9A-466E-96CE-2582E728CE74 Q35826171-B1EFE5E2-8ADE-40C6-8854-074DC550D04E Q35826692-8BF71333-C173-49F4-8277-2CDF1889E408 Q36171536-4182AE2C-028A-410A-8130-E87A829DF36A Q36481537-2433E1A8-74F9-410E-BB41-94D1D8454A2C Q36742228-6EC6E5A4-7075-4DE7-9DD2-99E595A125A1 Q37042563-59A74FA1-8180-4953-8DE8-E2913FEAE617 Q37060319-A7CE9A19-F766-4B70-BD55-F01EBD12A717 Q37123501-ED7743E1-36CA-4830-A819-498811FC074E Q37361294-B177A56D-0EE8-4C4F-9794-60FE5F58A68C Q37633417-D47143A6-5B3E-437C-9977-3E63C4977C71 Q37742119-CA2F1B3F-B11E-405B-981B-85E48FBA3394 Q37803320-12601F0D-EE37-46C8-872A-D463DE0C11AB Q37850183-D9FDE3E1-504A-4ED1-9557-E609FDFE32F8 Q38330424-BFD2B877-755E-41DF-AB7A-5392302A56C2 Q38521826-1AD1E8FB-A5A1-4B75-9340-0A821664A2E7 Q38581943-E661B24F-F8E5-4FC4-8A71-988EFF5C33CE Q38665463-2627A976-526D-4E6E-BBBF-8641CB4B6337

P2860

Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1

http://www.wikidata.org/entity/Q35122067

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Structural and immunogenicity ...... r derived from subtype A HIV-1

@ast

Structural and immunogenicity ...... r derived from subtype A HIV-1

@en

type

label

Structural and immunogenicity ...... r derived from subtype A HIV-1

@ast

Structural and immunogenicity ...... r derived from subtype A HIV-1

@en

prefLabel

Structural and immunogenicity ...... r derived from subtype A HIV-1

@ast

Structural and immunogenicity ...... r derived from subtype A HIV-1

@en

P1433

Q35122067-CDCDC01E-2C9C-449E-8213-E0CB65B98CCE

P1476

Q35122067-F59EAC5D-C1E8-4600-94B1-BA22E1B21824

P2093

Q35122067-0A1568B2-D1ED-4E58-8F92-5485C3221F1D

Q35122067-250F34BB-D626-4CD0-B6C2-5187C390300D

Q35122067-3D2AFBDF-12E7-44B4-8DEF-A2B6D890BE32

Q35122067-667F3FBE-AC6E-404A-9CB9-1094BA15FF9A

Q35122067-6FB260E8-9706-40C1-AE64-77CE3B76E427

Q35122067-701D7144-C6AF-4BDB-8FED-F337F80C0D45

Q35122067-798DB343-A576-43A1-94E2-ED3301DAD616

Q35122067-A59B25DB-427E-4A01-8E02-C2D35485FBF4

Q35122067-C448F3BF-C103-46D2-90C7-96C9F07FA23C

Q35122067-C861B371-9315-4151-AC0F-C2A236AC1956

P2860

Q35122067-0430BE71-4F47-423F-85FF-3486E9B16051

Q35122067-0784ED93-B794-4455-ABE5-14FFACF0187D

Q35122067-0CA1DEC2-A631-499C-81D3-CC7FAEECC1FD

Q35122067-11CE9792-7B73-404F-838D-5218AA25229E

Q35122067-1310579F-8410-47C1-B22C-5F926F3BE826

Q35122067-13BE65CF-C4FD-439D-92EC-B27C1C08CB63

Q35122067-15B5BE8F-A647-40AF-975F-2569CE82CCAC

Q35122067-1667B164-9588-4F51-8BBA-C65113ABF899

Q35122067-19092FB6-B835-4E75-BBCA-44ED0F01039A

Q35122067-20A317FB-6D72-4EC8-AA93-AF9115B8FEF0

P304

Q35122067-E1046F15-2032-45EC-BADB-1D638715E59F

P31

Q35122067-F927FA7F-4799-443B-9DA6-BDD4C1910D73

P356

Q35122067-EDFE17AB-A0B6-48F8-81CF-4FFDC268F2C5

P407

Q35122067-8B0E3605-F2FA-40B3-8C28-744F9ABC832F

P433

Q35122067-44F15E1C-CEA4-4065-BAC9-34471C1EDDA4

P478

Q35122067-2EEFE6D9-5F42-4EBF-8725-AC20C3323711

P577

Q35122067-7F5DE435-E7C3-42D2-8909-1BA547DB813F

P5875

Q35122067-F15AC017-93DB-4AB9-890B-45AFA32A2C02

P698

Q35122067-94BCC7DE-C2BA-4B93-AF05-D46D363EA1CB

P932

Q35122067-3E621353-4098-4AA8-AA35-0F551DF84109

P356

J.VACCINE.2009.06.037

P1433

P1476

Structural and immunogenicity ...... r derived from subtype A HIV-1

@en

P2093

Antu K Dey

http://www.w3.org/2001/XMLSchema#string

Emma T Crooks

http://www.w3.org/2001/XMLSchema#string

Gerald P Donovan

http://www.w3.org/2001/XMLSchema#string

James M Binley

http://www.w3.org/2001/XMLSchema#string

John P Moore

http://www.w3.org/2001/XMLSchema#string

Kenneth H Roux

http://www.w3.org/2001/XMLSchema#string

Michael Franti

http://www.w3.org/2001/XMLSchema#string

Paul J Maddon

http://www.w3.org/2001/XMLSchema#string

Ping Zhu

http://www.w3.org/2001/XMLSchema#string

Robert J Durso

http://www.w3.org/2001/XMLSchema#string

P2860

Dimeric association and segmental variability in the structure of human CD4

Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

Structural definition of a conserved neutralization epitope on HIV-1 gp120

Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates

Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity

Molecular architecture of native HIV-1 gp120 trimers

SPIDER and WEB: processing and visualization of images in 3D electron microscopy and related fields

Immunopathogenesis and immunotherapy in AIDS virus infections

GP120: target for neutralizing HIV-1 antibodies

P304

5120-5132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2009.06.037

http://www.w3.org/2001/XMLSchema#string

P407

P433

37

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26331153

http://www.w3.org/2001/XMLSchema#string

P698

19567243

http://www.w3.org/2001/XMLSchema#string

P932

4340663

http://www.w3.org/2001/XMLSchema#string